Editas Medicine announced the hiring of a new CEO on Thursday — the fourth top executive to lead the troubled maker of gene-editing treatments since 2014.
Gilmore O’Neill takes over as Editas’ CEO on June 1, the company said. He joins from Sarepta Therapeutics, where he served as chief medical officer.
Create a display name to comment
This name will appear with your comment